This paper examines arguments in favor and against the of patent rights on pharmaceuticals in the developing world as required by World Trade Organization membership. It emphasizes that these new pharmaceutical patents promise benefits and costs that differ with the characteristics of diseases. It also considers standard intellectual property and regulatory mechanisms that could be used to differentiate protection, and concludes that all have serious drawbacks. It then describes a new mechanism that would make differentiating protection a more feasible policy option.
With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.